Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 2 Interventional Results available

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

NCT03347188
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 25, 2026, 9:01 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 25, 2026, 9:01 PM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 25, 2026, 9:01 PM EDT
Active, not recruiting Phase 2 Interventional

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

NCT03456843
View directory record Official record
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

NCT01472185
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
57
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 25, 2026, 9:01 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

NCT02964338
View directory record Official record
Conditions
Chronic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
32
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Not applicable Interventional

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

NCT02770313
View directory record Official record
Conditions
Intermittent Fasting
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 2 Interventional

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

NCT00823680
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO5027838, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
35 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 25, 2026, 9:01 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

NCT07708727
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
12
States / cities
Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration

NCT02725710
View directory record Official record
Conditions
Other Abortion, Spontaneous Abortion
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 25, 2026, 9:01 PM EDT
Terminated Phase 3 Interventional Results available

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197145
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GW873140
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
52
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 25, 2026, 9:01 PM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

NSAIDS Following Elective Lumbar Spine Fusion

NCT07743606
View directory record Official record
Conditions
NSAID (Non-Steroidal Anti-Inflammatory Drug), Lumbar Spine Fusion, Ketorolac, Postoperative Pain
Interventions
Ketorolac, Naproxen, Standard Postoperative Pain Management
Drug · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 25, 2026, 9:01 PM EDT
Terminated Phase 2 Interventional

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07037420
View directory record Official record
Conditions
Acromegaly
Interventions
ALXN2420, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Torrance, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Postsurgical Pain Control for Lower Extremity Fractures

NCT02214810
View directory record Official record
Conditions
Lower Extremity Fractures.
Interventions
Bupivacaine/Exparel
Drug
Lead sponsor
Broward Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Not applicable Interventional Results available

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

NCT01653847
View directory record Official record
Conditions
End Stage Renal Failure With Renal Transplant
Interventions
Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Phase 3 Interventional Results available

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
77
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 25, 2026, 9:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment for Patients With Chronic Post-Concussion Symptoms

NCT03759808
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion Post Syndrome
Interventions
Psychological Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Not applicable Interventional Results available

Prepare for Your Diabetes Care

NCT05263310
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
Interventions
Prepare for Your Diabetes Care, Usual Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
75 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 9:01 PM EDT
Completed Not applicable Interventional Results available

Fully Remote Use of IpsiHand Device in Hemiparetic Stroke

NCT05965713
View directory record Official record
Conditions
Stroke, Hemiparesis, Spasticity as Sequela of Stroke, Brain Computer Interface, Chronic Stroke Survivors With Plegic Hand
Interventions
Neurolutions IpsiHand Upper Extremity Rehabilitation System, Home Exercise rehabilitation regimen Program (HEP)
Device · Other
Lead sponsor
Neurolutions, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 9:01 PM EDT